Arvinas to present Phase 1 biomarker data for ARV-102 Parkinson’s trial at 2026 MDS Congress

Bitget2026/10/01 20:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Arvinas scheduled late-breaking Phase 1 biomarker data for ARV-102 in Parkinson’s disease for presentation on Oct. 7, 2026.
Results have not been presented yet; the company flagged new oculomotor findings alongside biomarker readouts from the trial.
ARV-102 is an oral PROTAC designed to cross the blood-brain barrier and degrade LRRK2, a target linked to Parkinson’s disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arvinas Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610011601PRIMZONEFULLFEED9838018) on October 01, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Arvinas to present Phase 1 biomarker data for ARV-102 Parkinson’s trial at 2026 MDS Congress

You may also like

Crypto prices